press releases

Date Title Teaser

keyword search

Date Title  
01/18/23
bluebird bio, Inc. Announces Pricing of $120 Million Public Offering of Common Stock
SOMERVILLE, Mass. --(BUSINESS WIRE)--Jan. 18, 2023-- bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird”) today announced the pricing of its underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $6.00 per share, before deducting underwriting discounts and
 
01/18/23
bluebird bio, Inc. Announces Proposed Public Offering of Common Stock
SOMERVILLE, Mass. --(BUSINESS WIRE)--Jan. 18, 2023-- bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird”) today announced that it has commenced an underwritten public offering of 20,000,000 shares of its common stock. bluebird also intends to grant the underwriters a 30-day option to purchase up to an
 
01/09/23
bluebird bio Provides Update on Commercial Launch Progress, Program Milestones and 2023 Financial Outlook Ahead of Company Presentation at 41st Annual J.P. Morgan Healthcare Conference
- First commercially treated ZYNTEGLO patient apheresed in Q4 2022; first revenue anticipated in Q1 2023 - - lovo-cel BLA submission on track for Q1 2023; vector and drug product analytical comparability studies complete - - Company enters 2023 with c ash runway into Q1 2024 - SOMERVILLE, Mass.
 
01/06/23
bluebird bio Sells Second Priority Review Voucher for $95 Million
–   Non-dilutive capital further strengthens Company’s financial position – SOMERVILLE, Mass. --(BUSINESS WIRE)--Jan. 6, 2023-- bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that it has entered into a definitive agreement to sell its second Rare Pediatric
 
01/05/23
bluebird bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
SOMERVILLE, Mass. --(BUSINESS WIRE)--Jan. 5, 2023-- bluebird bio, Inc . (Nasdaq: BLUE) today announced that Andrew Obenshain , chief executive officer, bluebird bio, will present a corporate update at the 41 st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023 , at 7:30AM PT .
 
01/03/23
bluebird bio Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officer
SOMERVILLE, Mass. --(BUSINESS WIRE)--Jan. 3, 2023-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that Joseph Vittiglio , JD, has been appointed Chief Business and Legal Officer. Vittiglio brings more than 20 years of experience in the biopharmaceutical industry, with expertise in licensing,
 

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. bluebird bio disavows any obligation to update the information contained in such press releases after the date of their issuance.